First gene-transfer therapy approved for U.S. market.

The article offers information about the tisagenlecluecel which is a chimeric antigen receptor (CAR) T-cell immunotherapy approved by the U.S. Food and Drug Administration (FDA), and marketed as Kymriah by pharmaceutical company Novartis.